ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO875

Effects of Interleukin-6 Inhibition with Clazakizumab on Anemia and Iron Parameters in Patients with Kidney Failure

Session Information

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism

Authors

  • Neuen, Brendon Lange, The George Institute for Global Health, Sydney, New South Wales, Australia
  • Wolf, Myles, Duke University School of Medicine, Durham, North Carolina, United States
  • Catanese, Benjamin Peter, Duke University School of Medicine, Durham, North Carolina, United States
  • Heise, Mark A., CSL Behring LLC, King of Prussia, Pennsylvania, United States
  • Tricoci, Pierluigi, CSL Behring LLC, King of Prussia, Pennsylvania, United States
  • Chang, Anna Marie, CSL Behring LLC, King of Prussia, Pennsylvania, United States
  • Chertow, Glenn M., Stanford University School of Medicine, Stanford, California, United States
Background

Inflammation contributes to anemia and erythropoietin stimulating agent resistance in patients with kidney failure. Clazakizumab is a high affinity humanized monoclonal antibody that targets the interleukin-6 (IL-6) ligand and inhibits downstream IL-6 function. We recently reported an approximate 90% reduction in high-sensitivity C-reactive protein (hs-CRP) in patients receiving dialysis with a history of cardiovascular disease and/or diabetes. We sought to evaluate the effect of clazakizumab on anemia and iron parameters.

Methods

The Phase 2b component of the POSIBIL6ESKD Phase 2b/3 trial evaluated the effect of clazakizumab (2.5mg, 5mg, 10mg) or placebo administered every 4 weeks. The primary efficacy endpoint was the placebo-adjusted change in hs-CRP at 12 weeks. We prespecified as secondary endpoints the effects of clazakizumab on hemoglobin (Hb), iron parameters, and hepcidin, using mixed effects models for repeated measures.

Results

Among 127 participants, overall mean ± SD Hb and TSAT, median (25%, 75% range) ferritin and hepcidin were 10.7 ± 1.4 g/dL, 31 ± 11.7%, 1267 (735, 1598) µg/L and 232 (150, 306) ng/mL, respectively. The mean increase in Hb was 0.6 ± 1.5, 1.0 ± 1.3, 1.0 ± 1.4 g/dL at 12 weeks relative to baseline in the 2.5, 5, and 10 mg clazakizumab groups, respectively, compared with 0.4 ± 1.3 g/dL with placebo. These differences were not statistically significant. Clazakizumab significantly increased transferrin saturation and reduced hepcidin across all studied doses versus placebo, and had no clear effect on ferritin (Figure).

Conclusion

Through anti-IL6 effects, clazakizumab may improve iron utilization and contribute to anemia correction in patients receiving dialysis. Larger and longer-term data from the ongoing Phase 3 study will provide additional insights.

Funding

  • Commercial Support – CSL Behring